Pfizer Switches To Offense In Charity Co-Payment Suit Against HHS
Executive Summary
Pfizer is one of 10 pharma companies that have reached settlements with the US Department of Justice over their relationships with co-pay assistance foundations. It now seeks a declaratory judgement that proposed programs for its heart drug tafamidis do not violate the anti-kickback statute.
You may also be interested in...
US FDA Loses Orphan Exclusivity Case While HHS Wins Dismissal Of Pfizer Kickback Complaint
In rare loss for FDA, appeals court reverses district court decision tossing Catalyst’s suit over Orphan Drug Act, saying deference should not have been granted to agency’s interpretation. District court finds it is too early to rule on one Pfizer charity co-pay program but backs broad reading of Anti-Kickback Statute.
Teva Hit By US Suit Over Copaxone Copays
Government claims Teva’s payments to two foundations to cover Copaxone copays violated Anti-Kickback statute. Teva is bucking settlement trend in DOJ’s industrywide investigation of sponsor ties to charitable foundations.
Teva Is Latest To Be Hit With DOJ Suit Over Charity Copays
Government claims Teva’s payments to two foundations to cover Copaxone copays violated Anti-Kickback statute. Teva is bucking settlement trend in DOJ’s industrywide investigation of sponsor ties to charitable foundations.